Western Wealth Management LLC Purchases 107 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Western Wealth Management LLC increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,165 shares of the medical equipment provider’s stock after buying an additional 107 shares during the quarter. Western Wealth Management LLC’s holdings in Intuitive Surgical were worth $1,408,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ISRG. Creekmur Asset Management LLC grew its holdings in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 42 shares in the last quarter. MCF Advisors LLC grew its stake in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares in the last quarter. Able Wealth Management LLC bought a new position in Intuitive Surgical in the fourth quarter valued at approximately $28,000. Delos Wealth Advisors LLC grew its stake in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC bought a new position in Intuitive Surgical in the fourth quarter valued at approximately $30,000. 83.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Barclays raised their price target on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Citigroup raised their price target on Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Evercore ISI decreased their price target on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research note on Friday, July 19th. Piper Sandler lifted their target price on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Finally, Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $442.30.

Intuitive Surgical Trading Up 0.2 %

NASDAQ ISRG traded up $0.80 during midday trading on Monday, hitting $479.78. The company had a trading volume of 111,360 shares, compared to its average volume of 1,544,566. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $482.50. The firm has a 50-day moving average price of $443.20 and a 200-day moving average price of $407.87. The company has a market capitalization of $170.18 billion, a PE ratio of 86.46, a P/E/G ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the company posted $1.18 EPS. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 239 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $416.60, for a total transaction of $99,567.40. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,293,799.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $1,291,010.34. Following the sale, the executive vice president now owns 298 shares in the company, valued at approximately $136,522.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Robert Desantis sold 239 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $416.60, for a total value of $99,567.40. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,293,799.60. The disclosure for this sale can be found here. Insiders have sold 15,309 shares of company stock worth $6,642,470 in the last 90 days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.